Completed PHASE1 INTERVENTIONAL 1-arm NCT01026740

Evaluation of Penetration of Ceftobiprole Into Soft Tissue Determined by Microdialysis in Healthy Volunteers

An Exploratory Study to Evaluate the Penetration of Ceftobiprole Into Soft Tissue Determined by In Vivo Microdialysis in Healthy Volunteers

Sponsor: Basilea Pharmaceutica

Conditions Staphylococcal Skin Infections Streptococcal Infections

Interventions Ceftobiprole

Updated 6 times since 2017 Last updated: Jul 27, 2012 Started: Jun 30, 2007 Primary completion: Sep 30, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01026740, this PHASE1 trial focuses on Staphylococcal Skin Infections and Streptococcal Infections and remains completed. Sponsored by Basilea Pharmaceutica, it has been updated 6 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jun 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Basilea Pharmaceutica

Data source: Basilea Pharmaceutica

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.